EAS Certificate of Excellence in Lipidology 2.1
EAS Academy, Course Faculty, 313991
MODULE 10: EMERGING TREATMENTS OF DYSLIPIDEMIA
EAS Academy, Course Faculty, 313990
MODULE 9: LIFESTYLE AND NUTRITION IN CARDIOVASCULAR PREVENTION
EAS Academy, Course Faculty, 313989
MODULE 8. PHARMACOLOGICAL TREATMENT OF DYSLIPIDAEMIA - II
EAS Academy, Course Faculty, 313988
MODULE 7. PHARMACOLOGICAL TREATMENT OF DYSLIPIDAEMIA - I
EAS Academy, Course Faculty, 313987
MODULE 6: FAMILIAL DYSLIPIDAEMIAS
EAS Academy, Course Faculty, 313986
MODULE 5. THE 2019 EAS/ESC GUIDELINES
EAS Academy, Course Faculty, 313985
MODULE 4: GENETICS IN CARDIOVASCULAR DISEASE
EAS Academy, Course Faculty, 313984
MODULE 3: ARTERIAL WALL IN ATHEROSCLEROSIS
EAS Academy, Course Faculty, 313983
MODULE 2: LIPIDS, LIPOPROTEINS AND METABOLISM
EAS Academy, Course Faculty, 313982
MODULE 1: EPIDEMIOLOGY OF ASVD
EAS Academy, Course Faculty, 313981
ANGPTL 3 what we have learned from genetics?
EAS Academy, Marcello Arca, 313703
Position of omega 3 in Guidelines (as second choice after statins)
EAS Academy, Christie M. Ballantyne, 313704
Implementing systems biology to personalise medicine
EAS Academy, Johan Björkegren, 313706
The biology of PCSK9
EAS Academy, Bertrand Cariou, 313708
Translating science into guidance on the prevention of cardiovascular disease
EAS Academy, Guy De Baker, 313709
Prevention of cardiovascular diseases by glucose lowering drugs
EAS Academy, Stefano Del Prato, 313710
2. Behaviour change in CVD prevention
EAS Academy, Heinke Englert, 313712
Difficult cases to reach goal: Recurrent event on statin
EAS Academy, Michel Farnier, 313713
TG-rich lipoproteins as a risk factor
EAS Academy, Ruth Frikke-Schmidt, 313714
New therapeutic approaches
EAS Academy, John J. Kastelein, 313717
Difficult cases to reach goal: FH
EAS Academy, Meral Kayikcioglu, 313718
The Angiopoietin-like proteins, controlling lipoprotein metabolism
EAS Academy, Sander Kersten, 313719
Monoclonal antibody approaches targeting circulating PCSK9
EAS Academy, Ulf Landmesser, 313720
When do we need add on therapies to statin?
EAS Academy, Ulrich Laufs, 313721
Are the new EAS/ESC lipids goals reachable in clinical practice?
EAS Academy, Francois Mach, 313722
Immune modulation in atherosclerosis
EAS Academy, Ziad Mallat, 313723
Why and in whom is combination needed?
EAS Academy, Luis Masana, 313724
AI in CVD & beyond
EAS Academy, Jörg Menche, 313725
Case: Diabetic patient with MI - how to manage?
EAS Academy, Dirk Muller-Wieland, 313726
1. Precision nutrition and CVD management
EAS Academy, Jogchum Plat, 313727
What is the environment doing to cardiovascular health?
EAS Academy, Nicole Probst-Hensch, 313728
Risk stratification in very high risk patients is it of value?
EAS Academy, Faculty / Presenter(s), 313729
What do we know so far about bempedoic acid?
EAS Academy, Kausik Ray, 313730
siRNA based approaches targeting hepatic synthesis of PCSK9
EAS Academy, Kausik Ray, 313731
Global perspectives of cardiovascular disease, and impact of risk factors
EAS Academy, Gregory Roth, 313732
An update on the results of ODYSSEY outcomes
EAS Academy, Gabriel Steg, 313733
What is the landscape on lipid management today?
EAS Academy, Lale Tokgozoglu, 313734
The lipoprotein(a) story - from risk factor to causality to clinical trials
EAS Academy, Sotirios Tsimikas, 313735
Can polygenic scores reach clinical practice?
EAS Academy, Anne Tybjærg-Hansen, 313736
Can combination aid adherence ? (fixed dose, intolerance)
EAS Academy, Michal Vrablik, 313737
Anitschkow Lecture - The Oxidation Hypothesis of Atherosclerosis Revisited: A Pivotal Role of OxPL in Atherosclerosis, NASH and Inflammation
EAS Academy, Joseph L. Witztum, 313738
The value of omega 3: from biology to clinical practice
EAS Academy, Alberto Zambon, 313739
2.4.3 Bempedoic Acid - Ongoing studies
EAS Academy, Ulf Landmesser, 307377
Bempedoic Acid - The clinical experience
EAS Academy, Ulf Landmesser, 307376
Bempedoic Acid - Mechanism of action
EAS Academy, Alberico Catapano, 307375
Statins, including intolerance
EAS Academy, Lale Tokgozoglu, 307374
Omega 3 and fibrates
EAS Academy, Jan Borén, 307373
PCSK9 Inhibition including Inclisiran
EAS Academy, Ulf Landmesser, 307372
Ezetimibe
EAS Academy, Heinz Drexel, 307371
Management of dyslipidaemic patients in clinical practice
EAS Academy, Lale Tokgozoglu, 307370
EAS Introduction
EAS Academy, Lale Tokgozoglu, 307361
Guidelines: FH patients
EAS Academy, Jan Borén, 307369
Guidelines: Diabetic patients
EAS Academy, Heinz Drexel, 307368
Guidelines: ACS & very high risk patients
EAS Academy, Lale Tokgozoglu, 307367
Guidelines: the goals – why?
EAS Academy, Alberico Catapano, 307366
The new guidelines for dyslipidaemia
EAS Academy, Alberico Catapano, 307365
CV disease risk classification
EAS Academy, Lale Tokgozoglu, 307364
Lipoprotein metabolism and the causal role of LDL in atherosclerosis
EAS Academy, Jan Borén, 307363
Training Agenda Overview
EAS Academy, Alberico Catapano, 307362
MODULE 11: EXTRA MODULE (substitute for Congress)
EAS Academy, Faculty / Presenter(s), 293486
Dyslipidaemia treatment in ACS
EAS Academy, Lale Tokgozoglu, 287570
Cardiovascular risk assessment and lipid lowering for patients with DM - what do the guidelines say?
EAS Academy, Kausik Ray, 287569
A deep dive into EAS/ESC guidelines for dyslipidaemias
EAS Academy, Alberico Catapano, 287568
Important aspects related to diet and lifestyle in the new guidelines
EAS Academy, Gabriele Riccardi, 285189
Management of dyslipidaemias in different clinical settings
EAS Academy, Olov Wiklund, 285188
The approach of high - and very high risk patients in the new guidelines
EAS Academy, Lale Tokgozoglu, 285187
New recommendations and concepts in the new guidelines
EAS Academy, Alberico Catapano, 285186
Bempedoic acid : Mechanism of action
EAS Academy, Alberico Catapano, 282694
The clinical experience
EAS Academy, Maciej Banach, 282695
Ongoing studies
EAS Academy, Ulrich Laufs, 282696
Current available therapies: Ezetimbe
EAS Academy, Alberico Catapano, 282690
Current available therapies: Omega3 & fibrates
EAS Academy, Maciej Banach, 282692
Current available therapies: Statins
EAS Academy, Jan Borén, 282693
Current available therapies: PCSK9 inhibition
EAS Academy, Ulrich Laufs, 282691
Mendelian randomization
EAS Academy, Brian A. Ference, 282689
Guidelines: The goals why?
EAS Academy, Alberico Catapano, 282684
Guidelines: Diabetic patients
EAS Academy, Brian A. Ference, 282686
Guidelines: FH patients
EAS Academy, Jan Borén, 282687
Guidelines: ACS & very highrisk patients
EAS Academy, Ulrich Laufs, 282685
The new guidelines for dyslipidaemia
EAS Academy, Heinz Drexel, 282683
CV disease risk classification
EAS Academy, Lale Tokgozoglu, 282682
Lipoprotein metabolism & the casual role of LDL in Atherosclerosis
EAS Academy, Jan Borén, 282681
Course presentations: An Introduction to Clinical Lipidology, October 2019
EAS Academy, Lale Tokgozoglu, 282679
An Introduction to Clinical Lipidology
EAS Academy, Lale Tokgozoglu, 276242
Lessons from epidemiology and environmental CVD risk factors
EAS Academy, Salim Yusuf, 276243
Overview of the role of lipids in atherosclerosis
EAS Academy, Petri Kovanen, 276244
Genetic disorders of lipid metabolism – with special focus on familial hypercholesterolaemia
EAS Academy, Kees Hovingh, 276245
THE HDL STORY: TIME TO RECONSIDER?
EAS Academy, John Chapman, 272735
NEW LIPID DRUGS: IS LDL DONE, READY FOR NEW TARGETS?
EAS Academy, Erik Stroes, 272734
THE IMMUNE SYSTEM: THE NEXT GAME-CHANGER?
EAS Academy, Matthias Nahrendorf, 272733
SYSTEM-LEVEL ANALYSES OF INFLAMMATORY AND REPAIR MACROPHAGES REVEAL AN INTEGRATED CIRCUITRY OF LIPID AND EPIGENOMIC CHANGES
EAS Academy, Laszlo Nagy, 272732
CLINICAL EXPERIENCE WITH BEMPEDOIC ACID
EAS Academy, Christie M. Ballantyne, 272731
PHARMACOLOGY OF BEMPEDOIC ACID
EAS Academy, Giuseppe Danilo Norata, 272730
THE GENETIC EVIDENCE FOR INHIBITING THE CHOLESTEROL SYNTHESIS PATHWAY TO CONTROL LDL CHOLESTEROL
EAS Academy, Brian A. Ference, 272729
A DEEP LOOK TO THE RESULTS OF ODYSSEY OUTCOMES
EAS Academy, J. Wouter Jukema, 272722
REDUCE-IT: AN IN DEPTH ANALYSIS
EAS Academy, Christie M. Ballantyne, 272725
PCSK9 INHIBITION IN CLINICAL PRACTICE
EAS Academy, Francois Mach, 272721
OMEGA 3 AND CV BENEFIT A REVIEW OF THE CLINICAL TRIALS
EAS Academy, Aldo Pietro Maggioni, 272724
HOW GOOD ARE WE IN REACHING THE GOALS?
EAS Academy, Guy De Baker, 272720

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings